The bone substudy of MA.27: does bone make a difference?
Mené sur 300 patientes atteintes d'un cancer du sein après la ménopause, cet essai de phase III compare, du point de vue de l'évolution de la densité minérale osseuse à 2 ans, l'efficacité de l'exémestane et de l'anastrozole en traitement adjuvant
Oestrogen suppression using aromatase inhibitors is the cornerstone of adjuvant treatment for postmenopausal women with hormone receptor-positive early breast cancer. Both non-steroidal (anastrozole and letrozole) and steroidal (exemestane) aromatase inhibitors are more efficacious than is tamoxifen for reduction of recurrence of breast cancer. The investigators of MA.27—in which exemestane was compared with anastrozole—reported no difference for breast cancer-related outcomes between the two ...
The Lancet Oncology , commentaire, 2013